Novo Nordisk(US:NVO) Sou Hu Cai Jing·2025-09-11 09:35Core Points - Novo Nordisk announced a significant restructuring plan, aiming to reduce approximately 9,000 jobs globally, with around 5,000 positions expected to be cut in Denmark [1][2] - The restructuring is expected to generate annual cost savings of 8 billion Danish Kroner [2] - The new CEO, Maziar Mike Doustdar, initiated this plan, which includes merging departments to streamline operations and focus resources on core growth areas like diabetes and obesity [2][3] Financial Performance - Novo Nordisk has lowered its earnings forecast for the third time in 2025, now expecting a 6% decrease in operating profit growth compared to previous estimates [3] - The company reported a revenue of 154.94 billion Danish Kroner for the first half of 2025, with a net profit of 55.54 billion Danish Kroner [7] - The sales of the key product, semaglutide, reached 112.76 billion Danish Kroner in the same period [7] Market Competition - The expiration of core patents for semaglutide is expected to intensify competition in the global GLP-1 drug market, with many generic versions anticipated to enter the market [7][8] - Competitors like Eli Lilly have shown significant revenue growth, with a 37.64% increase in revenue year-on-year [7] - Domestic competitors in China, such as Innovent Biologics, are also preparing to launch their own GLP-1 drugs following the patent expiration [8]